Yates, Campbell, Hollis, Woodford, 1999) . TBI and HS result in secondary conditions such as inflammation, endothelial dysfunction, coagulopathy, hypoxia, and cerebral edema. Such secondary insults are highly linked, and include cross-talk between endothelial and coagulation pathways as key mediators. The primary insult to the brain occurs in the prehospital setting, involves irreversible destruction of neuronal tissue and cannot be treated. Hence, treatment strategies necessarily focus on prevention of secondary brain injury by maintaining adequate cerebral oxygenation and perfusion (Badjatia 2008) . Fluid resuscitation has historically been the mainstay in treating traumatic injuries. It plays a critical role in restoring and maintaining systemic and cerebral circulation in TBI patients (Myburgh et al., 2007 ). An ideal resuscitation fluid would therefore minimize cerebral edema, as well as attenuate neuronal damage, inflammation, and coagulopathy. However, current resuscitation strategies have failed to prevent this secondary brain injury. For this reason, recent advances in trauma research have focused on nextgeneration fluids and pharmacologic agents that may attenuate secondary brain injury. The aim of this review is to describe traditional resuscitation strategies for TBI combined with HS, and discuss the novel use of valproic acid (VPA) as a new pharmacologic agent in the treatment of TBI.
| C ONV E NT ION A L RE SUSCITA TION T RE AT M EN TS
TBI is often associated with hypovolemia, HS, and coagulopathy. In addition, microvascular injury may alter the permeability of the bloodbrain barrier (BBB), resulting in intravascular fluid leakage and cerebral edema. The ideal resuscitation strategy should aim to not only replace lost blood but also minimize secondary brain injury. Accordingly, current strategies focus on hemodynamic stabilization, maintaining systemic circulation, and optimizing cerebral perfusion (Hammell & Henning, 2009; Myburgh et al., 2007) . However, there is considerable debate about the most effective methods for treating blood loss associated with TBI.
| Fluid resuscitation
Prompt fluid resuscitation is the first-line therapy to restore the lost intravascular volume. As blood products are often unavailable at the scene of the injury, prehospital management is usually limited to infusion using crystalloids or colloids. Isotonic crystalloids are typically preferred over colloids (Myburgh et al., 2007; Perel & Roberts, 2012) and have served as the standard resuscitation fluid for some time. Yet, traditional resuscitation fluids such as crystalloids have no inherent prosurvival properties (Santry & Alam, 2010) , and in severely bleeding patients, aggressive crystalloid resuscitation does not result in any survival benefit (Bickell et al., 1994; Kwan, Bunn, & Roberts, 2003) . Moreover, several clinical studies have identified shortcomings of fluid resuscitation, such as hemodilution, hemostatic derangements, brain edema, and inflammation (Grande, Asgeirsson, & Nordstrom, 1997; Peiniger et al., 2011) . Such aggressive administration may even worsen outcomes by further exaggerating the cellular damage suffered during shock (Santry & Alam, 2010) . Preclinical studies showed that ongoing hemorrhage and coagulopathy are frequently not corrected by current resuscitation protocols using crystalloids and packed red blood cells (PRBCs) (Selby et al., 1996) . In addition, massive fluid resuscitation itself may even result in coagulopathy and hemodilution (Selby et al., 1996; Sondeen, Coppes, & Holcomb, 2013) .
Compared with other resuscitation fluids such as fresh frozen plasma (FFP) or colloids, normal saline resuscitation is furthermore associated with increased brain swelling (Jin, DeMoya, et al. (2012; Imam et. al. 2015) ; metabolic derangements ; elevated circulating markers of injury (Sillesen, Jin, et al., 2013) ; and increased activation of the endothelial, coagulation, and anticoagulation systems (Dekker, 2014c; Sillesen et al., 2014) .
These findings suggest that traditional fluid resuscitation with crystalloids is mostly supportive, and does not address the specific cellular dysfunction caused by shock and injury. Because of the increased awareness of the negative effects of massive transfusions, trauma care now favors "damage control resuscitation" consisting of minimal use of crystalloids, early hemorrhage control, and early administration of blood products (PRBC, FFP, and platelets in an appropriate ratio) (Kwan et al., 2003) .
| Blood product resuscitation
Commonly used blood products are PRBC, FFP, platelets, and fibrinogen. There is limited evidence concerning the use of PRBC in the setting of isolated TBI. The combination of TBI and HS likely mandates PRBC transfusion, with clinical data suggesting a survival benefit when FFP:PRBC ratios are maintained above 1:2 (Peiniger et al., 2011) . The benefits of FFP on the control of acute traumatic bleeding and coagulopathy are furthermore demonstrated in multiple clinical studies (Borgman et al., 2007; Duchesne et al., 2008; Maegele et al., 2008; Scalea et al., 2008; Wafaisade et al., 2010; Zehtabchi & Nishijima, 2009 ). In the setting of TBI, however, clinical data are conflicting. Some studies have indicated adverse outcomes associated with FFP administration (Anglin et al., 2013; Etemadrezaie et al., 2007) , while others have identified outcome benefits (Peiniger et al., 2011) . Preclinical studies demonstrated that early administration of FFP also appears to alter the clinical course following TBI by attenuating the degree of neurologic impairment, improving the rate of recovery, and preserving cognitive functions (Halaweish, 2015a) . These effects of blood products can even be detected at the level of gene transcription (Sillesen, Bambakidis, Dekker, Li, & Alam, 2017) , affecting the expression of genes involved in metabolism, platelet signaling, and inflammation. These data suggest that the therapeutic benefits of plasma resuscitation might be more extensive than solely through hemodynamic stabilization.
However, FFP transfusion is not without risk (Nascimento et al., 2010; Rossaint et al., 2016) . Such risks include transfusion-associated acute lung injury and circulatory overload, allergic reactions, and transmission of infectious diseases (Nascimento et al., 2010) . Moreover, the use of FFP and other blood products is challenging in prehospital settings or in underdeveloped areas because of logistical issues such as limited availability, requirement for refrigeration, short life after thawing, and the need for immediately available universal donor plasma. These challenges of FFP resuscitation have fueled the initiative to develop next-generation blood products that are low volume and shelf stable.
| Future directions of blood products and antifibrinolytics in traumatic bleeding
Lyophilized plasma, a freeze-dried plasma product developed in the 1930s, may solve the shortcomings of FFP resuscitation. It is logistically superior to FFP, as it can be stored as a powder for as long as 30 years, and subsequently reconstituted and administered within minutes following rehydration with water (Fu & Myhre, 1977) . Additionally, lyophilized plasma retains its factor function much better than FFP, and can be stored in ambient temperatures for extended periods of time.
Freeze-dried plasma has been shown to be as effective as FFP in large animal models of TBI and hemorrhage Halaweish et al., 2016) . Freeze-dried plasma is approved for clinical use in Europe and has been used by NATO forces for many years with good results Pusateri et al., 2016) . However, it is currently not approved by the Food and Drug Administration (FDA) for use in the United States. In the coming years, there is an urgent need for prospective investigations of blood products such as lyophilized plasma and fibrinogen, and antifibrinolytic drugs such as tranexamic acid (TXA).
There is currently a paucity of data concerning the use of TXA in TBI.
A recent Cochrane review concluded that TXA may reduce mortality, although the quality of the evidence is low and uncertainties remain (Ker, Roberts, Shakur, & Coats, 2015) . Furthermore, studies have suggested a reduction in the incidence of intracranial hemorrhage following TBI associated with administration of TXA (Zehtabchi, Abdel Baki, Falzon, & Nishijima, 2014) . Future randomized controlled trials should report on the clinical outcomes of treatment with TXA and fibrinogen to address some of the key unanswered questions in trauma-induced coagulopathy (Wong, Curry, & Stanworth, 2016) .
| N OV EL R ESUSC IT AT ION T ECH N I QU ES-E P I GE NE TI C M OD U LA TI ON U SI N G V P A
At present, there are no proven pharmacologic treatment options for TBI. However, the search for such therapeutic treatment of TBI has received considerable attention in recent years (Fukudome et al., 2012; Ichiyama et al., 2000) . A therapeutic strategy for modulating the cellular response to injury may be at the level of the epigenome. One class of promising drugs that affect the epigenome is histone deacetylase inhibitors (HDACIs). In pathologic conditions, such as TBI and HS, there is a decrease in histone acetylation, which limits gene transcription and impairs cellular homeostasis. However, agents such as VPA have been shown to act as HDACIs, thus altering gene transcription and thereby inducing a "prosurvival phenotype." The precise mechanisms underlying these protective effects are an active area of current research.
| TBI creates a genomic storm
The genomic response to injury is an important area of current research. Recent studies have revealed that traumatic injuries result in epigenetic changes via DNA methylation, phosphorylation, and acetylation (Wong & Langley, 2016) . The so-called "genomic storm" following injury occurs on an epigenetic level and modulates numerous cellular functions, protein expression, and pathways. These processes are considered "epigenetics," meaning that they affect the gene expression and resultant phenotype of the cell but do not alter the genome itself (Bernstein, Meissner, & Lander, 2007; Goldberg, Allis, & Bernstein, 2007) . Alam et al. showed that during hemorrhage and resuscitation, at least 7% of the genes and downstream pathways are differentially expressed (Alam, Stegalkina, Rhee, & Koustova, 2002) . Xiao et al. (2011) previously showed that after traumatic injury, expression of over 80% of the leukocyte transcriptome is altered. These changes occur rapidly after trauma and exhibit a long-lasting effect for months after the injury (Lipponen, Paananen, Puhakka, & Pitkänen, 2016; Xiao, 2011) . Modulating these epigenetic changes may thus be an important goal of therapy in patients with TBI.
| Acetylation status regulates gene expression and protein functions
Briefly, the human genome is organized into chromatin, a highly conserved complex of DNA and histone proteins. DNA transcription, and hence gene expression, is regulated by the acetylation and deacetylation of these histones. Histone deacetylases are enzymes that remove the acetyl group from the histone, making the DNA-histone structure more compact and therefore limiting transcription. In contrast, histone acetyltransferases weaken DNA-histone attraction, thereby unfolding the complex and making DNA more available for transcription (Delcuve, Khan, & Davie, 2012) . A homeostatic balance between histone deacetylases and histone acetyltransferases typically exists in cells.
However, dysregulation of acetylation homeostasis has been suggested to play a key role in the pathogenesis of cancers and neurodegenerative diseases. Moreover, as noted above, dysregulation of acetylation homeostasis has also been implicated as an important pathologic mechanism in the body's response to traumatic injuries. Thus, pharmacologic agents that can alter histone acetylation may be promising new therapeutic strategies for trauma, as they can rapidly and reversely modify the transcription of desirable genes.
Although histones were considered the main target of HDACIs, we now know that nonhistone proteins involved in key cellular functions such as the cell cycle, stress response, cytoskeleton dynamics, signaling, repair/healing/remodeling, communication, and proliferation are equally involved (Glozak, Sengupta, Zhang, & Seto, 2005) . At least 50 such nonhistone proteins have been well characterized (Kim & Bae, 2011) , but this list is rapidly growing. In one study, 3,600 acetylation sites (in 1,750 human proteins) were identified, which regulated nearly all nuclear and many key cytoplasmic processes (Choudhary, 2009 ).
This makes acetylation a regulatory mechanism that is as prevalent and important as phosphorylation (Kouzarides, 2000; Norris, Lee, & Yao, 2009 ). Acetylation of nonhistone proteins is actually even more important than histones in the setting of severe shock and/or TBI. While it takes some time to produce phenotype changes through modulation of gene transcription, direct (nontranscriptional) acetylation of regulatory proteins is extremely fast and thus more relevant for rapidly lethal conditions such as shock or TBI. In short, there are many features that DEKKER ET AL. | 713 make acetylation an attractive therapeutic target: It is rapid, completely reversible, and can be altered by drugs that are already in clinical use.
| VPA restores normal cellular acetylation
A growing body of literature suggests that VPA may alter gene expression and protein functions following TBI Dekker, 2014b; Halaweish et al., 2015b) . VPA has been in clinical use as a mood-stabilizing and antiepileptic drug since the 1970s. In high doses, however, VPA acts as a HDACI. High-dose VPA has been shown to improve survival in otherwise lethal models of HS, polytrauma (Alam et al., 2009 , sepsis, and combined TBI with HS (Halaweish et al., 2015b,c; Jepsen et al., 2014; Jin, Duggan, et al., 2012a ). Yet, the pre- 
| VPA alters cell survival and cell death pathways
One of the first studies that investigated the effects of hemorrhage and resuscitation on histone acetylation demonstrated that crystalloid resuscitation results in a predominantly deacetylation profile in animal models, and that treatment with HDACIs was able to reverse it (Lin et al., 2006) . Our research group sought to better understand this effect of HDACI treatment at the level of gene expression. Using a porcine model of TBI1HS, we performed a high-throughput analysis of cerebral gene profiling following resuscitation with either hextend or hextend1VPA. We hypothesized that treatment with VPA would significantly alter the early transcription of genes in pathways related to cell survival, which may explain its previously observed neuroprotective effects such as reduced brain lesion size and swelling. We found that 1,668 probe sets mapping to 370 known genes were differentially expressed between hextend versus hextend1VPA groups. These genes Spinal cord injury animal model Abdanipour et al., 2012; Darvishi et al., 2014 Reduced inflammation TBI animal model Jin et al., 2012a; Nikolian et al., 2016b; Tai et al., 2014 Glioma cell in vitro model Ichiyama et al., 2000 Spinal cord injury animal model Abdanipour et al., 2012; Darvishi et al., 2014 Restoration of BBB function TBI animal model Nikolian et al., 2016; Yu et al., 2013 Focal cerebral ischemia animal model Wang et al., 2011 Spinal cord injury animal model Lee et al., 2012 Attenuated platelet dysfunction TBI animal model Dekker et al., 2014a; Sillesen, Johansson, et al., 2013 Decreased metabolism and attenuated mitochondrial dysfunction TBI animal model Dekker et al., 2014b; Hwabejire, Jin, et al., 2013b Modulation of cell signaling TBI animal model Dekker et al., 2014b; Nikolian et al., 2016b BBB 5 blood-brain barrier; TBI 5 traumatic brain injury.
were mapped to, among others, pathways related to cell death, apoptosis, and necrosis (Dekker, 2014b) . These findings support our hypothesis that VPA alters important genes and pathways that could improve survival.
| VPA reduces inflammation and BBB dysfunction
As described previously, secondary brain injury includes an acute inflammatory response with BBB disruption, activation of immune cells, and cerebral edema. The anti-inflammatory properties of VPA treatment have been described previously in models of sepsis, hemorrhage, and TBI (Jin, Duggan, et al., 2012; Liu et al., 2014; Shang et al., 2010) .
In addition, showed that VPA modulates genes related to inflammation, cell signaling, cell adhesion, and endothelial growth. Dash et al. (2010) VPA-induced reduction of matrix metalloproteinase-9, a protease that disrupts BBB function (Lee et al., 2012; Wang, et al., 2011) . This was furthermore associated with decreased degradation of tight junction and basement membrane-associated proteins, such as zona occludin-1 (ZO-1), and claudin-5 (Lee et al., 2012) . This is in line with data from Nikolian and Dekker et al, 2016 ., who found that VPA significantly increases expression of ZO-1, laminin, and claudin-5. Expression of glucose transporter 1, a marker of barrier-type endothelial cells, was also increased in the VPA treatment group. Moreover, in vitro monolayers treated with VPA significantly decreased permeability relative to anoxic controls . Taken together, these results suggest that protective mechanisms of VPA may involve decreasing inflammation and correcting BBB dysfunction.
3.6 | VPA attenuates platelet dysfunction the VPA group reached cognitive normalization significantly faster than the NS controls. In addition, small animal studies showed improved spatial memory (Dash et al., 2010) and functional recovery (Dash et al., 2010; Tai et al., 2014; Yu et al., 2013) when VPA was added to the treatment protocol. In animal models of spinal cord trauma, VPA treatment was associated with reduced secondary damage, improved locomotor scores (Abdanipour, Schluesener, & Tiraihi, 2012; Darvishi, Tiraihi, Mesbah-Namin, Delshad, & Taheri, 2014) , and more rapid recovery (Abdanipour et al., 2012) (Table 1) .
| F U TU R E DI R EC TI ONS
4.1 | VPA treatment shows a promising translation to human patients
One of the challenges with new treatment strategies is the translation of outcomes from animal models to patients in the clinical setting. Animal models are imperfect, and there are several differences between porcine and human species in both physiology and genome. For example, the porcine physiology is hypercoagulable relative to the human coagulation system. One of the main limitations of research in traditional and pharmacological resuscitation is the lack of human studies.
Importantly, Sillesen et al. (2016) infusion, steroid metabolism, lipid synthesis, and vitamin metabolism were also upregulated . In part 2 of the ongoing phase 1 trial, the effects of VPA in trauma patients with HS will be studied (ClinicalTrials.gov identifier NCT01951560). Phase 2 and 3 trials have already been approved for funding and will commence in the next few years.
| VPA dosing needs further refinement
Most experiments described in this review used a dose of 300 mg/kg, which is 6 times higher than the dose used in humans for the treatment of seizures. While these high doses improve outcomes in animal models, they may be associated with side effects in human patients. For example, several investigators have shown that 300-mg/kg and 400-mg/kg doses of VPA may be toxic, with respiratory and cardiac arrest occurring shortly after infusion (Burns, Baer, Darlington, Dubick, & Wade, 2012) . Acute VPA overdose results in hypotension, respiratory depression, thrombocytopenia, and metabolic disorders (Manoguerra et al., 2008) . In addition, chronic VPA use ( > 4 weeks) has been associated with thrombocytopenia, platelet dysfunction (Davidson et al., 2011; Gesundheit, Kirby, Lau, Koren, & Abdelhaleem, 2002; Gidal et al., 1994; Kis et al., 1999; Manoguerra et al., 2008) , and acquired von Willebrand disease (Serdaroglu, Tutuncuoglu, Kavakli, & Tekgul, 2002; Verrotti et al., 1999) . A dose as low as 60 mg/kg a day has been found to be biologically active in cancer studies, which led to our hypothesis that lower doses might also be beneficial for trauma patients.
As detailed above, our recent test of lower-dose VPA (150 mg/kg) in a TBI1HS survival model showed promising results in terms of neurologic recovery, cognitive outcomes, and lesion size (Halaweish et al., 2015b) .
A low-dose VPA strategy was further supported by the first results of our phase 1 trial demonstrating that VPA is biologically effective in healthy humans when given at a dose of 120 mg/kg.
| There are potential problems with pan-HDACI treatment
VPA is cheap, well tested in multiple animal models, and approved worldwide by regulatory agencies. However, it has been shown to affect several different types of histones. Briefly, there are five different histone deacetylase classes: Class I, IIa, IIb, III, and IV. Within these classes, there are 18 different histone deacetylase isoforms (HDAC 1-11 and SIRT 1-7). All isoforms have very different physiological functions, cellular locations, and organ distributions (Halaweish et al., 2015c) . As VPA is a nonspecific pan-inhibitor, it may create significant potential for toxicity and side effects. An important area of current research is the development of isoform-specific HDACIs that are both more potent and also target specific organs. Our research group is currently comparing isoform-specific HDACIs and pan-HDACIs, and investigating the synergistic effects between various HDACIs and other cytoprotective strategies.
In particular, the use of HDAC6 inhibition has been shown to be effective in models of sepsis (Li et al., 2015) . 
